Succinylcholine: Indications, Dosing, Contraindications, and Management

Pharmacologic Profile

• Succinylcholine is a depolarizing neuromuscular blocker that produces rapid‑onset muscle paralysis ideal for rapid‑sequence intubation, with onset ≈ 1 min and duration 4–6 min. 1

Dosing Recommendations

Adult

• Standard intubation dose: 1.0 mg kg⁻¹ IV. 1

Pediatric (age‑specific)

• < 1 month: 1.8 mg kg⁻¹
• 1 month – 1 year: 2.0 mg kg⁻¹
• 1 year – 10 years: 1.2 mg kg⁻¹
• > 10 years: 1.0 mg kg⁻¹

Special Populations

• In nerve‑agent poisoning or after pyridostigmine pretreatment, the dose should be significantly reduced. 1
• Patients with myasthenia gravis require ≈ 50 % of the usual dose, and succinylcholine is generally avoided. 4

Absolute Contraindications

• Personal or familial history of malignant hyperthermia. 5
• Skeletal‑muscle myopathies (e.g., Duchenne or Becker muscular dystrophy). 1
• Administration during the acute phase of injury (24 h – 7–10 days) after major burns, extensive trauma, denervation, upper‑motor‑neuron injury, or spinal‑cord injury. 6
• Prolonged immobilization (> 3 days). 6
• Any neuromuscular disease that predisposes to receptor up‑regulation. 6

Life‑Threatening Adverse Effects

• Severe hyper‑kalemia and possible cardiac arrest can occur in patients with up‑regulated acetylcholine receptors (e.g., muscular dystrophy, recent burns). 6
• Malignant hyperthermia may be triggered, presenting with masseter spasm, generalized rigidity, tachycardia, and marked hyperpyrexia. 6
• Dantrolene must be immediately available wherever succinylcholine is used. 6

Management of Hyper‑Kalemia

• If cardiac arrest follows succinylcholine, suspect hyper‑kalemia and treat aggressively with:

  • Calcium gluconate or calcium chloride for membrane stabilization.
  • Insulin + glucose (0.1 U kg⁻¹ insulin with 400 mg kg⁻¹ glucose) to shift potassium intracellularly.
  • Sodium bicarbonate to alkalinize urine and promote potassium excretion.
  • Hyperventilation to reduce PaCO₂.
  • CPR for 10–12 minutes as needed.

• Definitive potassium elimination should begin early: loop diuretics, potassium‑binding agents, and hemodialysis for refractory cases. 6

• Extended monitoring of serum potassium and creatine kinase for 2–4 hours after stabilization to detect rebound hyper‑kalemia. 6

Management of Malignant Hyperthermia

• Immediate dantrolene administration, discontinue all triggering agents, apply aggressive cooling, and provide supportive care for hyper‑kalemia and metabolic acidosis. 6

Monitoring Requirements

• Intra‑operative: continuous ECG and heart‑rate monitoring from induction until at least 2 minutes post‑intubation; special vigilance for bradycardia in children 28 days – 8 years. 6

• Continuous pulse‑oximetry throughout the procedure. 6

• Post‑operative (pediatric): monitor until full return of airway reflexes, spontaneous ventilation, and ability to maintain airway; child must remain awake ≥ 20 minutes in a quiet environment before discharge. 6

• High‑risk patients: serial serum potassium and creatine‑kinase measurements; neuromuscular monitoring is strongly recommended when receptor up‑regulation is possible. 6

Alternative Neuromuscular Blocker

• Rocuronium at ≥ 0.9 mg kg⁻¹ (preferably 1.0–1.2 mg kg⁻¹) is the recommended alternative for rapid‑sequence intubation when succinylcholine is contraindicated. 2, 7
• Rocuronium 1.2 mg kg⁻¹ yields a first‑pass intubation success rate of ~79 %, comparable to succinylcholine’s 82–84 %. 1
• Duration of action: 30–60 minutes (vs. 4–6 minutes for succinylcholine). 1
• Sugammadex should be immediately available to reverse rocuronium if needed. 4

Clinical Pitfalls

• Do not repeat doses of succinylcholine; use a non‑depolarizing agent for subsequent paralysis. 6
• A negative family history does not exclude malignant hyperthermia susceptibility; patients may still develop MH after uneventful prior anesthetics. 1
• Underdosing rocuronium (< 0.9 mg kg⁻¹) may result in inadequate intubating conditions. 1
• Pretreatment with defasciculating doses of non‑depolarizing agents does not protect against hyper‑kalemia in high‑risk patients. 6
• Do not extubate children prematurely; ensure they are fully awake, have cleared secretions, and can maintain upper‑airway reflexes. 6

ESAIC Recommendations for Succinylcholine and Rocuronium in Rapid Sequence Intubation

First‑Line Depolarizing Agent

• The European Society of Anaesthesiology and Intensive Care (ESAIC) strongly recommends succinylcholine 1–2 mg/kg IV for rapid sequence intubation in both adults and children, based on moderate‑quality evidence; it provides complete glottic relaxation within ≈ 60 seconds, thereby minimizing the period of an unprotected airway in full‑stomach patients. 8

• ESAIC advises that cricoid pressure should be released if direct laryngoscopy proves difficult, to improve glottic exposure and facilitate successful intubation. 8

• ESAIC emphasizes that emergency laparotomy patients are at especially high risk for aspiration because of bowel obstruction, abdominal distension, sepsis, and opioid administration, reinforcing the need for rapid airway protection. 8

Alternative Non‑Depolarizing Agent

• When succinylcholine is contraindicated, ESAIC recommends using rocuronium 1.0–1.2 mg/kg IV (minimum 0.9 mg/kg) as the alternative neuromuscular blocker. 8

• ESAIC notes that the 2023 guideline continues to endorse succinylcholine as the first‑line agent for rapid sequence intubation despite the availability of sugammadex for rocuronium reversal, because succinylcholine offers an unmatched combination of rapid onset and very short duration of action. 8

Succinylcholine Dosing and Recommendations for Rapid Sequence Induction

Recommended Dose and Evidence Strength

• The European Society of Anaesthesiology and Intensive Care (ESAIC) strongly recommends an intravenous succinylcholine dose of 1–2 mg/kg for rapid sequence intubation in adults, citing moderate‑quality evidence that this dose achieves complete glottic relaxation within approximately 60 seconds, the fastest onset among neuromuscular blockers. 9
• For a typical adult patient, administer succinylcholine 1.0–1.5 mg/kg IV for rapid sequence induction, which is the dose range most commonly used to ensure optimal intubating conditions while avoiding under‑dosing. 9

Patient‑Specific Considerations

• In older adults (e.g., patients around 60 years of age), the risk of postoperative delirium and anesthesia‑induced hypotension is higher, but this does not modify the recommended succinylcholine dose for rapid sequence induction; dose adjustments pertain to maintenance anesthetic management rather than the induction agent. 9

Contraindications and Alternative Neuromuscular Blocker

• If any absolute contraindication to succinylcholine exists (e.g., personal/family history of malignant hyperthermia, skeletal muscle myopathies, recent major burns, extensive trauma, denervation, upper motor neuron injury, prolonged immobilization, or other neuromuscular diseases), use rocuronium 0.9–1.2 mg/kg instead, with sugammadex immediately available for reversal. 9

Succinylcholine Use: Indications, Contraindications, Dosing, Monitoring, and Alternatives

1. Indications & Contraindications

• Succinylcholine is recommended only as a single‑dose bolus for rapid‑sequence intubation (RSI); continuous infusion for prolonged neuromuscular blockade is not endorsed (Critical Care Medicine guideline) 10.
• Absolute contraindications include a personal or family history of malignant hyperthermia and any neuromuscular disease that predisposes to acetylcholine‑receptor up‑regulation (e.g., muscular dystrophies, myopathies) (British Anaesthesia guideline) [11][10].

2. Single‑Dose Dosing Recommendations

• Adults: 1.0 mg/kg IV based on actual body weight (Critical Care Medicine guideline) [12][13].
• Obese adults (BMI ≥ 40 kg/m²): same 1.0 mg/kg dose calculated on actual body weight, not ideal or lean body weight (Critical Care Medicine guideline) 12.
• Patients with myasthenia gravis: reduce the dose to approximately 50 % of the standard adult dose; however, succinylcholine is generally avoided in this population (Critical Care Medicine guideline) 14.

3. Monitoring Requirements

• Intra‑operative monitoring should include continuous ECG and heart‑rate surveillance from induction until at least 2 minutes after intubation (Critical Care Medicine guideline) 10.
• Neuromuscular monitoring (train‑of‑four) is strongly recommended when receptor up‑regulation is possible (e.g., in patients with risk factors) (Critical Care Medicine guideline) 14.

4. Management of Life‑Threatening Complications

• Malignant hyperthermia: immediate discontinuation of triggering agents, administration of dantrolene 2–2.5 mg/kg IV every 10 minutes (maximum 300 mg per dose) until symptoms regress, and aggressive cooling measures (British Anaesthesia guideline) 11.
• Hyperkalemia‑induced cardiac arrest: treat with calcium gluconate or chloride for membrane stabilization, insulin + glucose, sodium bicarbonate, hyperventilation to lower PaCO₂ (Anaesthesia guideline) 13; continue CPR as needed.

5. Preferred Alternative: Rocuronium

• Intubating dose: 0.9–1.2 mg/kg IV (preferably 1.0–1.2 mg/kg for optimal conditions) (Critical Care Medicine guideline) 15.
• Onset and duration: onset ≈ 60 seconds at 1.2 mg/kg; duration 30–60 minutes, providing a longer window of paralysis compared with succinylcholine (4–6 minutes) (Critical Care Medicine guideline) 15.
• Reversal: sugammadex must be immediately available for rapid reversal when rocuronium is used (Critical Care Medicine guideline) 15.

6. Rocuronium Continuous Infusion Protocol (ICU Use)

These infusion parameters are derived from Critical Care Medicine recommendations [15][14].

Rocuronium Preferred Over Succinylcholine for Intubation in Severe Traumatic Brain Injury

1. Mortality Advantage of Rocuronium in Severe Head Injury

• In patients with severe or critical traumatic brain injury (abbreviated injury score ≥ 4), use of succinylcholine for rapid‑sequence intubation was associated with a 44 % mortality rate versus 23 % with rocuronium, yielding an odds ratio of 4.10 (95 % CI 1.18–14.12). The Society of Critical Care Medicine (SCCM) notes that this finding comes from a single retrospective observational study, limiting the certainty of the evidence. [16][17]

2. Hyperkalemia Risk Specific to Trauma Patients

• Traumatic brain injury patients who have been immobilized for more than three days, have extensive tissue injury, or experience marked muscle wasting are at heightened risk for life‑threatening hyperkalemia after succinylcholine administration because of up‑regulated nicotinic acetylcholine receptors across skeletal muscle. This risk is recognized as an absolute contraindication to succinylcholine in this population. 18

3. Recommended Rocuronium Dosing and Expected Efficacy

• For rapid‑sequence intubation in head‑injured patients, administer rocuronium intravenously at 0.9–1.2 mg kg⁻¹ (preferably 1.0–1.2 mg kg⁻¹). At the higher dose (≈1.2 mg kg⁻¹), onset occurs within 60 seconds and first‑pass intubation success is roughly 79 %, comparable to succinylcholine’s 82–84 % success rate. The longer duration of action (30–60 minutes) is considered acceptable given the superior safety profile. [16][17]

4. Post‑Intubation Analgosedation Protocol

• After rocuronium‑facilitated intubation, initiate a protocolized analgosedation regimen immediately to prevent intra‑procedural awareness during the 30–60 minute paralysis window. Involving clinical pharmacists or structured checklists improves timely delivery of sedation and analgesia. [16][17]

5. Guideline Consensus and Evidence Grading

• The 2023 SCCM guidelines issue a conditional recommendation (low‑quality evidence) that either rocuronium or succinylcholine may be used when no contraindications exist. However, the guidelines explicitly highlight the single study showing increased mortality with succinylcholine in severe head injury, thereby favoring rocuronium in real‑world practice. [16][17]

6. Emergency Management of Succinylcholine‑Induced Hyperkalemia

7. Management of Suspected Malignant Hyperthermia (if succinylcholine is inadvertently used)

• Administer dantrolene 2–2.5 mg kg⁻¹ intravenously every 10 minutes (maximum 300 mg per dose) until clinical signs resolve. This recommendation is supported by evidence from the British Journal of Anaesthesia (2020). [19][20]

All facts are derived from cited peer‑reviewed sources and reflect the current consensus of the Society of Critical Care Medicine and related specialty societies.